Key facts
- It has raised $17.2M; the latest was Seed Round ($17.2M) in Oct 2024.
- Notable investors include Mission BioCapital, Illumina Ventures, Root Ventures, Michael Stoppelman, Sutter Hill Ventures — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Integrated BioSciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Integrated BioSciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Integrated BioSciences
Operator of a biosciences company intended to create cellular rejuvenation with optogenetics and small molecules. The company combines synthetic biology and machine learning to control cellular stress responses, enabling medical professionals to efficiently treat neurodegeneration, cancer, diabetes, osteoarthritis, and other age-associated diseases.
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2022
- Employees
- 17
- Website
- integratedbiosciences.com/
- Ownership
- Privately Held (backing)
Integrated BioSciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Integrated BioSciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Integrated BioSciences in its N-PORT filings yet. We sweep new filings monthly.